Consensus IGM Biosciences, Inc.

Equities

IGMS

US4495851085

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
10.44 USD -1.88% Intraday chart for IGM Biosciences, Inc. -0.10% +25.63%

Evolution of the average Target Price on IGM Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c2fdd3250261d940097bcf0.VlbaVjWPgUN_kvY3s95adP8h133-bZI7rMZWbsAvzPQ.DmfiPXnLwDQ5pcdFwr08B6dOmzCaP-FB_aE_H5d3tL5mBYAnYcSsIhrDpw~ea663549358bcf481a715b03851e33f1
HC Wainwright Adjusts IGM Biosciences Price Target to $12 From $7, Maintains Neutral Rating MT
RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept MT
BofA Securities Downgrades IGM Biosciences to Neutral From Buy, Adjusts Price Target to $8 From $20 MT
HC Wainwright Downgrades IGM Biosciences to Neutral From Buy, Cuts Price Target to $7 From $11 MT
Wedbush Raises IGM Biosciences' PT to $20 From $16, Adjusts Downstream Funding Assumptions; Keeps Outperform Rating MT
RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk MT
Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $11 From $17, Keeps Buy Rating MT
Stifel Trims IGM Biosciences' Price Target to $25 From $26, Keeps Buy Rating MT
RBC Cuts Price Target on IGM Biosciences to $8 From $11, Keeps Sector Perform, Speculative Risk MT
Wedbush Lowers IGM Biosciences' Price Target to $16 From $19, Keeps Outperform Rating MT
HC Wainwright Adjusts IGM Biosciences' Price Target to $17 From $22, Keeps Buy Rating MT
Morgan Stanley Adjusts Price Target on IGM Biosciences to $15 From $20, Maintains Equal-Weight Rating MT
RBC Cuts Price Target on IGM Biosciences to $11 From $17, Maintains Sector Perform Rating, Speculative Risk Qualifier MT
Wedbush Cuts IGM Biosciences' PT to $19 From $37, Notes Focus of Aplitabart in mCRC, Removes Potential Imvotamab Oncology Revenues; Keeps Outperform Rating MT
JPMorgan Adjusts Price Target on IGM Biosciences to $19 From $26, Maintains Neutral Rating MT
RBC Cuts Price Target on IGM Biosciences to $17 From $21, Maintains Sector Perform, Speculative Risk MT
Wedbush Lowers IGM Biosciences' Price Target to $37 From $41, Adjusts Future Financing Assumptions; Keeps Outperform Rating MT
Truist Securities Lowers Price Target on IGM Biosciences to $25 From $37, Maintains Buy Rating MT
JPMorgan Chase Adjusts Price Target on IGM Biosciences to $26 From $27, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on IGM Biosciences to $20 From $30, Maintains Equal-Weight Rating MT
HC Wainwright Adjusts Price Target on IGM Biosciences to $22 From $45, Maintains Buy Rating MT
Wedbush Cuts IGM Biosciences' Price Target to $41 From $58, Adjusts Assumptions for IGM-8444, Imvotamab; Keeps Outperform Rating MT
RBC Cuts Price Target on IGM Biosciences to $21 From $24, Keeps Sector Perform Rating, Speculative Risk Qualifier MT
RBC Boosts Price Target on IGM Biosciences to $24 From $22, Maintains Sector Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
10.44 USD
Average target price
21.5 USD
Spread / Average Target
+105.94%
High Price Target
48 USD
Spread / Highest target
+359.77%
Low Price Target
12 USD
Spread / Lowest Target
+14.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering IGM Biosciences, Inc.

HC Wainwright
RBC Capital Markets
BofA Securities
Wedbush
Morgan Stanley
Stifel Nicolaus
JPMorgan Chase
Truist Securities
Jefferies & Co.
Baird
Guggenheim
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings